Namibian Dr. Annelle Zietsman Provides Insights on Experimental Cancer Drug blinatumomab (blina)

In our interview with Dr. Annelle Zietsman, we gained valuable insights into the experimental cancer drug Blinatumomab. Leonard Witbeen from Future Media News conducted the interview, seeking information on the drug’s potential benefits and its status in the Namibian market.

The conversation commenced with Wydby informing Dr. Zietsman about the BBC’s report on Blinatumomab, touted as an exciting new cancer drug gentler than chemotherapy. Dr. Zietsman, initially unaware of the drug, requested details on its scientific name and purpose.

After a brief pause, Witbeen provided the information, clarifying that Blina Blinatumomab, referred to colloquially as “Blina,” is a biological drug currently undergoing trials. Dr. Zietsman confirmed that it is indeed an experimental biological drug and emphasized that it is far from being available in the market, both globally and in Namibia.

Dr. Zietsman explained the drug’s typical journey through stages of clinical trials, including phases one, two, and three. Only after receiving approval from regulatory bodies such as the FDA in the United States and local ethics committees can a drug become available for public use. As Blinatumomab is still in the research phase, it is not accessible to the general population.

Leonard questioned whether the Namibian market and the Ministry of Health are aware of the drug. Dr. Zietsman clarified that the drug is not yet available anywhere in the world for general use and is only accessible to patients participating in clinical trials.

Dr. Zietsman further stressed that Blinatumomab  is not a universal or miracle drug for all cancers. Instead, it is designed for specific cancers and individuals with biomarkers that can be targeted by this class of biological drugs.

The interview concluded with gratitude from Witbeen, acknowledging Dr. Zietsman’s time and expertise. Zietsman reiterated that the drug is part of a larger group of biological drugs being tested, emphasizing the ongoing nature of research and development in the field of cancer treatment.

The conversation sheds light on the importance of understanding the experimental nature of certain cancer drugs and the rigorous process they undergo before becoming available to the public.